Ameriprise Financial is reaffirmed as a buy due to resilient macroeconomic trends, strong organic growth, and robust dividend coverage. The company leads its peers in return on equity (ROE), maintains double-digit earnings growth, and continues to attract high-quality advisor teams and client inflows. Despite some analyst earnings per share (EPS) downgrades and mixed market performance, Ameriprise's low payout ratio and investment-grade credit rating support the safety of its dividends. Valuation remains attractive based on forward price-to-earnings (P/E) ratios, with forecasts indicating meaningful upside and total return potential exceeding 10% by 2027.
Ameriprise Financial is spotlighted with a reaffirmed buy rating as of November 3, 2026. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 03, 2026 02:02 WIB: out of 142 priced US Financials stocks, 117 rose and 25 fell. Notable movers include GLXY at USD 14.72 with a 1-day change of -8.00% and 100% buy order activity, RKT at USD 13.81 with a 1-day change of +7.89% and 92% buy order activity, and RIOT at USD 11.82 with a 1-day change of -7.73% and 98% sell order activity.
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
The FDA placed Bright Minds Biosciences' planned Phase 2 epilepsy trial for BMB-101 on partial clinical hold due to toxicity findings in mice and insufficient pharmacokinetic and juvenile-toxicity data. This action caused a sharp decline in the compa...
NEAR governance approved a plan to reduce the maximum annual issuance of the NEAR token from 2.5% to 1.6%. This change aims to slow the rate at which new tokens enter circulation, potentially impacting staking rewards by lowering them. The plan inclu...
